ArticleNPJ digital medicine2026
Interpretable graph deep learning framework for drug synergy prediction by integrating functional and clinical similarities.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Tumor heterogeneity and drug resistance limit single-agent therapies, making combination treatments essential. However, traditional screening methods are costly and inefficient. Here, we present DSimSynergy, a graph deep learning framework for predicting drug synergy. It constructs drug similarity networks from biological process and clinical applications, then learns drug representations through graph convolution on these networks. Subsequently, it combines them with graph attention representations of drug molecular fingerprints and cell line gene expressions to predict synergy scores for drug combinations. Comprehensive benchmarking on multiple independent datasets demonstrates that DSimSynergy consistently outperforms state-of-the-art methods. Model interpretability analysis revealed key genes and pathways underlying drug synergy, while validation on clinical patient and cohort data demonstrated good clinical translational potential and discovered the molecular mechanisms by which drugs generate synergistic effects through "pathway complementary networks". DSimSynergy efficiently identifies synergistic combinations, reducing experimental costs while elucidating biological mechanisms to overcome resistance and guide personalized treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.